Corcept Therapeutics Incorporated Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Medical - Pharmaceuticals |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Corcept Therapeutics Incorporated (CORT) holds an ST Score of 64.0 out of 100 (B), with its strongest factor being Profitability (A+) and its weakest Valuation (D). Analysts rate CORT Buy across 26 ratings with a $125.33 average price target (+0.1% vs the current $113.76).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationD
All factor grades
- ProfitabilityA+
- MomentumA
- Financial StrengthA-
- GrowthB
- ForecastC+
- ValuationD
- Piotroski6/9
Contact
CORT stock: frequently asked questions
What is CORT's ST Score?
Corcept Therapeutics Incorporated (CORT) has an ST Score of 64.0 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CORT a buy, sell, or hold?
Wall Street's consensus rating on CORT is Buy based on 26 analyst ratings. Our own ST Score grades it B (64.0/100). This is data, not investment advice — always do your own research.
What is CORT's valuation grade?
Corcept Therapeutics Incorporated (CORT) earns a valuation grade of D, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CORT's growth grade?
Corcept Therapeutics Incorporated (CORT) earns a growth grade of B, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CORT's profitability grade?
Corcept Therapeutics Incorporated (CORT) earns a profitability grade of A+, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CORT's financial strength grade?
Corcept Therapeutics Incorporated (CORT) earns a financial strength grade of A-, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CORT?
The average analyst price target for Corcept Therapeutics Incorporated (CORT) is $125.33 from 26 analysts, which is +0.1% versus the recent price of $113.76.
What is CORT's Piotroski score?
Corcept Therapeutics Incorporated (CORT) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.